Recombinant Human VEGFA, Met1-Arg191, was produced in Sf 9 (baculovirus)-derived in an animal component free process under cGMP guidelines.
Lyophilized from a 0.2 μm filtered solution in HCl.
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED50 for this effect is 1-6 ng/mL.
The specific activity of recombinant human VEGF165 is approximately 1.7 x 10^3 U/μg, which is calibrated against recombinant human VEGF165 WHO Standard (NIBSC code: 02/286).
Predicted Molecular Mass: 19.2 (monomer) kDa
SDS-PAGE: 19-21 kDa, reducing conditions
N-terminal Sequence Analysis:
<0.01 EU per 1 μg of the protein by the LAL method.
>97%, by SDS-PAGE with silver staining.
Avoid repeated freeze-thaw cycles.
12 months, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 100 μg/mL in sterile PBS. Alternatively, reconstitute at 500 μg/mL in sterile 4 mM HCl.
Our GMP proteins are produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.